Original Article
Toll-like Receptor 4 Polymorphisms and Aspergillosis in Stem-Cell Transplantation
N Engl J Med 2008; 359:1766-1777October 23, 2008
- Abstract
Background
Toll-like receptors (TLRs) are essential components of the immune response to fungal pathogens. We examined the role of TLR polymorphisms in conferring a risk of invasive aspergillosis among recipients of allogeneic hematopoietic-cell transplants.
Methods
We analyzed 20 single-nucleotide polymorphisms (SNPs) in the toll-like receptor 2 gene (TLR2), the toll-like receptor 3 gene (TLR3), the toll-like receptor 4 gene (TLR4), and the toll-like receptor 9 gene (TLR9) in a cohort of 336 recipients of hematopoietic-cell transplants and their unrelated donors. The risk of invasive aspergillosis was assessed with the use of multivariate Cox regression analysis. The analysis was replicated in a validation study involving 103 case patients and 263 matched controls who received hematopoietic-cell transplants from related and unrelated donors.
Results
In the discovery study, two donor TLR4 haplotypes (S3 and S4) increased the risk of invasive aspergillosis (adjusted hazard ratio for S3, 2.20; 95% confidence interval [CI], 1.14 to 4.25; P=0.02; adjusted hazard ratio for S4, 6.16; 95% CI, 1.97 to 19.26; P=0.002). The haplotype S4 was present in carriers of two SNPs in strong linkage disequilibrium (1063 A/G [D299G] and 1363 C/T [T399I]) that influence TLR4 function. In the validation study, donor haplotype S4 also increased the risk of invasive aspergillosis (adjusted odds ratio, 2.49; 95% CI, 1.15 to 5.41; P=0.02); the association was present in unrelated recipients of hematopoietic-cell transplants (odds ratio, 5.00; 95% CI, 1.04 to 24.01; P=0.04) but not in related recipients (odds ratio, 2.29; 95% CI, 0.93 to 5.68; P=0.07). In the discovery study, seropositivity for cytomegalovirus (CMV) in donors or recipients, donor positivity for S4, or both, as compared with negative results for CMV and S4, were associated with an increase in the 3-year probability of invasive aspergillosis (12% vs. 1%, P=0.02) and death that was not related to relapse (35% vs. 22%, P=0.02).
Conclusions
This study suggests an association between the donor TLR4 haplotype S4 and the risk of invasive aspergillosis among recipients of hematopoietic-cell transplants from unrelated donors.
Media in This Article
Figure 1
Cumulative Incidence of Invasive Aspergillosis and Death after Hematopoietic Stem-Cell Transplantation, According to Donor TLR4 Haplotype Status and CMV Serostatus in the Discovery Study.Table 1
Characteristics of Transplant Donors and Recipients in the Discovery and Validation Studies.Article Activity
- Article
Over the past 20 years, invasive aspergillosis has become increasingly frequent among recipients of allogeneic hematopoietic-cell transplants, with an incidence rate of up to 12%.1 Despite the availability of new azole and echinochandin antifungal drugs, the outcome remains poor, with a 1-year mortality of 50 to 80%, making invasive aspergillosis one of the leading infection-related causes of death among recipients of allogeneic hematopoietic-cell transplants.1,2 Identification of patients who are at increased risk for infection before transplantation could facilitate the development of effective prevention strategies.
Toll-like receptors (TLRs) are transmembrane proteins on the surface of immune cells that detect conserved molecular motifs known as “microbe-associated molecular patterns” from a variety of organisms. They interact with several adapter proteins to activate transcription factors, leading to the production of inflammatory cytokines and the activation of adaptive immunity.3,4 Aspergillus species activate innate immune cells through both toll-like receptor 2 (TLR2) and toll-like receptor 4 (TLR4).5-10
Common polymorphisms in TLR genes have been associated with susceptibility to several infections.11 Mutations in TLR adapter molecules (i.e., interleukin-1 receptor–associated kinase 4 [IRAK4], inhibitor of nuclear factor κ B kinase γ [IKKγ], and inhibitor of nuclear factor κ B α [IκBα]) cause rare inherited immunodeficiencies, further demonstrating the importance of genetic variability in the TLR signaling pathway.11 In the transplant recipient, inhaled molds may interact with epithelial cells from the recipient or phagocytic cells from the donor lineage; both cells express TLRs. We hypothesized that polymorphisms in TLR genes from the donor and the recipient may influence susceptibility to invasive aspergillosis in recipients of hematopoietic-cell transplants. To test this hypothesis, we analyzed the frequencies of single-nucleotide polymorphisms (SNPs) for four candidate TLR genes in a cohort of recipients of hematopoietic-cell transplants and unrelated donors.
Methods
Patients
All patients who received an allogeneic hematopoietic-cell transplant from the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance between 1989 and 2004 were eligible for this analysis. Specimens were obtained and DNA was extracted by our Human Immunogenetics Program in an ongoing process that was based solely on the availability of specimens, and no preferences were given to any specific clinical variables. For the discovery and validation studies, patients were selected sequentially from the overall pool of specimens available at the time the respective studies were conducted, and no patient was included in both studies.
For the discovery study, we identified 374 patients with available DNA who underwent their first allogeneic hematopoietic-cell transplantation from an unrelated donor between 1995 and 2003. Cases were identified from microbiologic and histopathological reports in clinical charts and classified as “probable” or “proven” invasive aspergillosis, with the use of definitions developed by the Mycoses Study Group of the National Institute of Allergy and Infectious Diseases and the European Organization for Research and Treatment of Cancer.12 Among the 374 patients, 38 were excluded for one or more of the following reasons: both the donor and recipient had a nonwhite or unknown race or ethnic group (32 patients), invasive aspergillosis occurred before the first or after a second transplantation (5), the diagnosis of invasive aspergillosis was classified as “possible” (3), and infection was due to an invasive mold other than aspergillus species (2).
For the validation study, we used a matched case–control design and included recipients of hematopoietic-cell transplants from related donors. A minimal number of 100 cases with at least one matched control was required for odd ratios of approximately 2.3, 2.0, and 1.8, with 80% power and a 5% type I error rate, for allelic frequencies of 10%, 20%, and 30%, respectively (calculated with the use of Quanto 1.2.3 software).13 Among the 223 patients in whom invasive aspergillosis occurred between 1989 and 2004, identified from the overall pool from the Human Immunogenetics Program, 120 patients were excluded for one of the following reasons: the donor had an unknown or a nonwhite race or ethnic group (67 patients), invasive aspergillosis occurred before the first or after a second transplantation (37), or the diagnosis of invasive aspergillosis was classified as “possible” (16). For each of the 103 remaining patients with invasive aspergillosis, 1 to 6 controls were matched according to age (<40 or ≥40 years), donor race or ethnic group, donor type, and year of transplantation (±5 years). Among 404 selected controls, 263 had available DNA and were included in the validation study. A subgroup analysis was performed to account for differences in the types of hematopoietic-cell transplants.
Graft-versus-host disease (GVHD) and cytomegalovirus (CMV) disease were diagnosed according to standard definitions.14-16 All patients received systemic antibiotic prophylaxis during the period of neutropenia, as well as prophylactic acyclovir, trimethoprim–sulfamethoxazole or dapsone, and fluconazole, until day 75 after hematopoietic-cell transplantation. A small number of patients (35 patients in the discovery study and 13 in the validation study) received itraconazole or voriconazole prophylaxis on the basis of the individual physician's decision or as part of a prospective, randomized study of the efficacy of itraconazole versus fluconazole prophylaxis.17
Patients and donors gave written informed consent for data collection, cell storage, and cryopreservation. Batched genotyping was performed according to protocols approved by the institutional review board of the Fred Hutchinson Cancer Research Center. The study was also approved by the Western Institutional Review Board (Olympia, WA).
Single-Nucleotide Polymorphisms
Previously identified minimal haplotype-tagging SNPs from the Innate Immunity Program in Genomic Applications database (http://innateimmunity.net/) were used for each candidate gene. Five additional SNPs that have previously been reported to be associated with human diseases were also genotyped. A total of 20 SNPs in TLR2, TLR3, TLR4, and TLR9 were identified with the use of a mass-spectrometry genotyping platform (Sequenom).18
Statistical Analysis
Hardy–Weinberg equilibrium and pairwise linkage disequilibrium were calculated with the use of the genwh and pwld programs developed in Stata software, version 9.2 (StataCorp). We considered an R2 value of more than 0.90 to represent strong linkage disequilibrium. Haplotypes were inferred with the use of the expectation-maximization algorithm implemented in the Decipher program (SAGE).19 We grouped all rare haplotypes (frequencies <2%) into one group for each gene. All analyses were performed for white donors, white recipients, or both; race was reported by the donors and recipients.
The probability of invasive aspergillosis according to TLR variants at 6 and 36 months after transplantation was estimated with the use of cumulative incidence curves, with censoring of data at the date of the last follow-up and with death, second transplantation, and morphologic relapse treated as competing risks.20 A period of 36 months was chosen because all cases of invasive aspergillosis in the discovery cohort had occurred during this period, and a period of 6 months was chosen in order to assess early invasive aspergillosis. Comparisons of the risks of invasive aspergillosis and death on the basis of the TLR variants were performed with the use of univariate Cox regression models, unless otherwise specified. Multivariate Cox models were used to evaluate the relative hazards associated with TLR variants. Candidate covariates were selected from the factors associated with aspergillosis or death in the univariate analysis (P≤0.15) or in previous studies.1 The covariates were entered one by one in a pairwise model together with the significant TLR variant and kept in the final model if they remained significant (P<0.05) or altered the association with the TLR variant by more than 10%. Conditional logistic regression was used in the analysis of the data from the case–control validation study, with the use of similar methods for selecting variables.
Because of the large number of statistical comparisons made in the discovery study, the P values presented should be interpreted cautiously. To facilitate this interpretation, we report P values that would remain significant with the application of traditional Bonferroni corrections for multiple comparisons. Among the 20 SNPs tested, two pairs of SNPs were found to be in strong linkage disequilibrium: TLR4 1063 A/G and TLR4 1363 C/T (R2=0.96), and TLR9 +1174 G/A and TLR9 1635 A/G (R2=0.96); these findings are consistent with previous observations.21,22 Since the analyses for these SNPs are redundant, 18 independent tests were considered for multiple-testing correction. For haplotypes, we considered four independent tests (i.e., one for each gene). Since the case–control study was performed for validation and was limited to TLR4, no correction for multiple testing was applied in this study.
Results
Discovery Study
The discovery study included 336 patients who underwent allogeneic hematopoietic-cell transplantation after a myeloablative-conditioning regimen (Table 1Table 1
Characteristics of Transplant Donors and Recipients in the Discovery and Validation Studies.). The median follow-up time among patients who survived was 84 months (range, 5 to 124). Among the 336 patients, 33 had proven or probable invasive aspergillosis.Univariate Analysis
To assess the risk of invasive aspergillosis according to TLR SNPs and haplotypes in recipients and donors of hematopoietic-cell transplants, we estimated the cumulative incidence of infection 6 months and 36 months after hematopoietic-cell transplantation. Two SNPs in donors of hematopoietic-cell transplants (1063 A/G [D299G] and 1363 C/T [T399I]), which were in strong linkage disequilibrium (R2=0.96), influenced the risk of the development of invasive aspergillosis (see Table S1 in the Supplementary Appendix, available with the full text of this article at www.nejm.org). The association was stronger at 6 months (for TLR4 1363T, the cumulative incidence of invasive aspergillosis was 22% in the presence of the allele vs. 5% in its absence; P=0.002) (Table 2Table 2
Univariate Analysis of the Association of Donor TLR4 Polymorphisms with the Cumulative Incidence of Invasive Aspergillosis in the Discovery Study.) and remained significant after correction for multiple testing (P=0.03). Another donor SNP in TLR4, −2604G, tended to influence the risk of invasive aspergillosis when the comparison was made at 36 months (cumulative incidence of invasive aspergillosis, 4% in the presence of the allele vs. 13% in its absence; P=0.01), but the association was no longer present when correction for multiple testing was applied (P=0.20).Three TLR4 haplotypes in donors (H5, H6, and H8) were or tended to be associated with an increased risk of invasive aspergillosis (Table S2 in the Supplementary Appendix). Since these three haplotypes included −2604G and +12186G carriers, and H6 also included 1363T carriers, a three-locus haplotype was created (Figure 1DFigure 1
Cumulative Incidence of Invasive Aspergillosis and Death after Hematopoietic Stem-Cell Transplantation, According to Donor TLR4 Haplotype Status and CMV Serostatus in the Discovery Study.). Haplotypes S3 and S4 influenced the risk of the development of invasive aspergillosis. For S3, the association was present only at 36 months (17% in its presence vs. 6% in its absence, P=0.01; P=0.04 with adjustment for multiple testing); for S4, a haplotype that included 1363T carriers, the association was stronger at 6 months (22% vs. 5%, P=0.002; P=0.03 with adjustment for multiple testing).Multivariate Analysis
The final SNP model included TLR4 −2604G (adjusted hazard ratio, 3.22; 95% confidence interval [CI], 1.02 to 10.16; P=0.05) (Table 3Table 3
Multivariate Analyses of the Association of Donor TLR4 Polymorphisms with the Risk of Invasive Aspergillosis in Both Studies.) and 1363T (adjusted hazard ratio, 4.96; 95% CI, 1.52 to 16.24; P=0.008). In the final haplotype model, the hazard ratio for S3 was 2.20 (95% CI, 1.14 to 4.25; P=0.02) and the hazard ratio for S4 was 6.16 (95% CI, 1.97 to 19.26; P=0.002). Both final models also included seropositivity for CMV in the patient, the donor, or both (hazard ratio, 4.90; 95% CI, 1.51 to 15.91; P=0.008) and acute GVHD (hazard ratio, 3.11; 95% CI, 1.22 to 7.90; P=0.02) in the haplotype model, indicating that donor S4 (or TLR4 1363T), CMV seropositivity, and acute GVHD were independent risk factors for invasive aspergillosis. The interaction between positivity for CMV and S4 did not influence the risk of invasive aspergillosis (P=0.23).Validation Study
The characteristics of the patients in the case–control study were similar to those of the patients in the initial study (Table 1), but the validation study included recipients of transplants from both related and unrelated donors, and the median time to invasive aspergillosis after transplantation was shorter (68 days vs. 100 days). The association of donor TLR4 S4 with the risk of invasive aspergillosis was confirmed in the validation study (adjusted odds ratio, 2.49; 95% CI, 1.15 to 5.41; P=0.02) (Table 3). In the subgroup analysis, the association between S4 and invasive aspergillosis was significant among recipients of transplants from unrelated donors (adjusted odds ratio, 5.00; 95% CI, 1.04 to 24.01; P=0.04) (Table 3) but not among recipients of transplants from related donors (adjusted odds ratio, 2.29; 95% CI, 0.93 to 5.68; P=0.07). No association between S3 and invasive aspergillosis was observed in the validation study. However, in this group, haplotype S2 tended to increase the risk of invasive aspergillosis (adjusted odds ratio, 1.86; 95% CI, 1.01 to 3.44; P=0.05); this haplotype was present in TLR4 +12186G carriers, and this allele also increased the risk of invasive aspergillosis in the SNP model (adjusted odds ratio, 2.18; 95% CI, 1.13 to 4.21; P=0.02).
Risk Assessment before Hematopoietic-Cell Transplantation
Since CMV serologic testing and TLR4 haplotype analysis can both be used before hematopoietic-cell transplantation to evaluate the risk of invasive aspergillosis and death, patients were stratified into groups according to CMV serologic status (CMV-negative vs. CMV-positive) and status with respect to donor haplotype S4 (S4-negative vs. S4-positive) (Figure 1). In the discovery study, invasive aspergillosis occurred in 1 of 83 CMV-negative and S4-negative patients (1%), 14 of 136 CMV-positive and S4-negative patients (10%), and 5 of 23 CMV-negative and S4-positive or CMV-positive and S4-positive patients (22%) (Figure 1A). Since the number of patients in some groups was small, all patients who were CMV-positive, S4-positive, or both were grouped together (Figure 1B and 1C). The cumulative incidence of invasive aspergillosis increased from 1% in 83 CMV-negative and S4-negative patients to 12% in 159 patients who were CMV-positive, S4-positive, or both (hazard ratio, 11.95; 95% CI, 1.60 to 89.34; P=0.02, after adjustment for pretransplantation covariates). The cumulative incidence of death not related to relapse increased from 22% among CMV-negative and S4-negative patients to 35% among patients who were CMV-positive, S4-positive, or both (hazard ratio, 1.88; 95% CI, 1.10 to 3.20; P=0.02, after adjustment for pretransplantation covariates) (Table 4Table 4
Multivariate Analysis of Pretransplantation Risk Factors for Death Not Related to Relapse in the Discovery Study.). In the validation study, the odds ratio for invasive aspergillosis among patients who were CMV-positive and S4-positive or CMV-negative and S4-positive, as compared with those who were CMV-negative and S4-negative, was 3.10 (95% CI, 1.29 to 7.45; P=0.01), and for patients who were CMV-positive and S4-negative, the odds ratio was 1.54 (95% CI, 0.84 to 2.85; P=0.16), after adjustment for pretransplantation and post-transplantation covariates.Discussion
These data suggest an association between the TLR4 haplotype S4 in donors of hematopoietic-cell transplants (haplotype frequency, 6%) and invasive aspergillosis in recipients of hematopoietic-cell transplants. This haplotype was present in carriers of two SNPs in strong linkage disequilibrium (1063G and 1363T) that influence TLR4 function.
The TLR genes were initially identified through their homology with the Toll gene in Drosophila melanogaster, which triggers the production of drosomycin and is required for effective protection against fungal infections.23 Mammalian TLR4 was first recognized as the transmembrane receptor for lipopolysaccharide, a key component for the detection of gram-negative bacteria.24 Subsequent studies have shown that TLR4 is also involved in the recognition of fungal ligands, including mannan (derived from Candida albicans)25 and glucuronoxylomannan (derived from Cryptococcus neoformans).26 Several studies have highlighted the role of TLR2 and TLR4 in the innate immune recognition of aspergillus species.5-10 Although TLR2-dependent responses have been shown to augment β-1,3 glucan stimulation through dectin-1, the microbial Aspergillus fumigatus TLR2 and TLR4 ligands have not yet been identified.9
TLR4 1063G and 1363T SNPs have been reported to be associated with susceptibility to infections caused by gram-negative bacteria,27,28 C. albicans,29 brucella species,30 respiratory syncytial virus,31 and Plasmodium falciparum.32 Persons who are heterozygous for the 1063G and 1363T SNPs are hyporesponsive to lipopolysaccharide, as measured by the bronchospastic response after inhalation of endotoxin.33 Furthermore, airway epithelial cells isolated from heterozygous persons were reported to have a deficient response to lipopolysaccharide, suggesting that 1063G and 1363T act in a dominant fashion with respect to the wild-type allele.33 However, monocytes and whole blood isolated from heterozygous subjects did not have abnormal responses to lipopolysaccharide,34,35 suggesting that the effects of these polymorphisms may vary among cell types or experimenta l conditions or that polymorphisms other than 1063G and 1363T interfere with the results.
A possible limitation of this study is the fact that genetic associations can be biased by population stratification.36 However, we observed a similar association in two separate studies, suggesting that a confounding effect is unlikely. Another limitation is the possibility that TLR4 SNPs and haplotypes associated with invasive aspergillosis are in linkage disequilibrium with SNPs in another gene, located nearby, that are responsible for the alterations in the phenotype. However, the fact that TLR4 is an essential receptor for aspergillus species and that TLR4 1063 A/G and 1363 C/T SNPs impair TLR4 function suggests that the polymorphisms in TLR4 are probably responsible for the observed phenotypes. Finally, polymorphisms may not be directly associated with invasive aspergillosis, but instead may be associated with other factors, such as acute GVHD or CMV seropositivity, that also influence the end point.37,38 However, this possibility is unlikely, given the multivariate analysis, which identified donor S4, acute GVHD, and CMV seropositivity as three independent risk factors.
Polymorphisms in genes encoding interleukin-10, tumor necrosis factor receptor type 2, TLR1, and TLR6 have previously been shown to influence susceptibility to various clinical forms of aspergillosis.39-43 However, the TLR4 polymorphisms that we found to be significantly associated with invasive aspergillosis were derived from donor cells in hematopoietic-cell transplants, not from recipient cells. Thus, patients who undergo hematopoietic-cell transplantation are chimeras for whom the immune system is derived in part from the recipient (e.g., epithelial cells) and in part from the donor (hematopoietic cells). Polymorphisms in TLR genes expressed on the surface of polymorphonuclear neutrophils10 or resident macrophages, which are from the donor's cell lineage, may impair cellular activation and antifungal responses.
The association of S4 with an increased risk of invasive aspergillosis, observed in the discovery study, was also observed in the validation study, which included recipients of transplants from related donors and from unrelated donors. In the subgroup analysis, the association was present among the patients who received transplants from unrelated donors, as it was in the discovery study, but it was not present among the recipients of transplants from related donors. The reason for these differences is unknown. They may result from differences in the level of immunosuppression between recipients of hematopoietic-cell transplants from related donors and recipients of transplants from unrelated donors, or they may be explained by the relatively small size of the groups after stratification. In any case, these findings should be interpreted in the context of the limitations of subgroup analyses.44 Further studies will be needed to clarify this issue.
In conclusion, this study suggests an association between TLR4 haplotypes in unrelated donors and an increased risk of invasive aspergillosis among recipients of allogeneic hematopoietic-cell transplants. The identification of donors who have an increased risk of severe infection may have implications for prevention strategies in recipients of allogeneic hematopoietic-cell transplants.
Supported by grants from the Swiss Foundation for Medical and Biological Grants (1121), the Swiss National Science Foundation (81LA-65462), and the Leenaards Foundation (to Dr. Bochud); and the U.S. National Institutes of Health (CA18029, CA15704, AI054523, AI051468, AI33484, HL87690, HL088201, and HL69860). Some of the results of this study were obtained with the use of SAGE software, which is supported by a grant from the National Center for Research Resources (RR03655).
Dr. Marr reports receiving consulting fees from Astellas, Basilea, Enzon, Merck, Pfizer, and Schering-Plough, being a member of a data and safety monitoring board for a trial of antifungal prophylaxis for Schering-Plough, and receiving research support from Astellas, Pfizer, Enzon, and Merck; Dr. Boeckh, being a member of a data and safety monitoring board for a human immunodeficiency virus trial for Pfizer, receiving research support from Pfizer and Merck, and receiving consulting fees from Enzon; and Drs. Bochud, Boeckh, Chien, and Marr, having a pending application for a patent on TLR4 SNPs and haplotypes and the risk of aspergillosis. No other potential conflict of interest relevant to this article was reported.
We thank Jeremy Smith, Ravinder K. Sandhu, Craig Silva, Christopher Davis, Peter Choe, and Sanam Hussain for assistance in data collection and handling; Jeffrey Stevens, Gary J. Olsem, Tera R. Matson, Terry Stevens-Ayers, Jennifer Gravley, and Kimberly Harrington for technical assistance; and Véronique Erard for critical review of an earlier version of the manuscript.
Source Information
From the Institute for Systems Biology (P.-Y.B., M.J., S.D.R., S.L., A.A.); the Program in Infectious Diseases (P.-Y.B., K.A.M., W.M.L., A.U., M.B.), the Clinical Research Division (J.A.H.), and Quantitative Genetic Epidemiology, Division of Public Health Sciences (L.P.Z.), Fred Hutchinson Cancer Research Center; and the Department of Medicine, University of Washington (J.W.C., K.A.M., W.M.L., J.A.H., M.B.) — all in Seattle.
Address reprint requests to Dr. Boeckh at the Vaccine and Infectious Disease Institute, Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109, or at mboeckh@fhcrc.org.
- References
References
1
Marr KA ,Carter RA ,Crippa F ,Wald A ,Corey L . Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-917
CrossRef | Web of Science | Medline2
Upton A ,Kirby KA ,Carpenter P ,Boeckh M ,Marr KA . Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-540
CrossRef | Web of Science | Medline3
Beutler B . Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004;430:257-263
CrossRef | Web of Science | Medline4
Akira S ,Uematsu S ,Takeuchi O . Pathogen recognition and innate immunity. Cell 2006;124:783-801
CrossRef | Web of Science | Medline5
Braedel S ,Radsak M ,Einsele H , et al. Aspergillus fumigatus antigens activate innate immune cells via toll-like receptors 2 and 4. Br J Haematol 2004;125:392-399
CrossRef | Web of Science | Medline6
Mambula SS ,Sau K ,Henneke P ,Golenbock DT ,Levitz SM . Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem 2002;277:39320-39326
CrossRef | Web of Science | Medline7
Meier A ,Kirschning CJ ,Nikolaus T ,Wagner H ,Heesemann J ,Ebel F . Toll-like receptor (TLR) 2 and TLR4 are essential for Aspergillus-induced activation of murine macrophages. Cell Microbiol 2003;5:561-570
CrossRef | Web of Science | Medline8
Netea MG ,Warris A ,Van der Meer JW , et al. Aspergillus fumigatus evades immune recognition during germination through loss of toll-like receptor-4-mediated signal transduction. J Infect Dis 2003;188:320-326
CrossRef | Web of Science | Medline9
Gersuk GM ,Underhill DM ,Zhu L ,Marr KA . Dectin-1 and TLRs permit macrophages to distinguish between different Aspergillus fumigatus cellular states. J Immunol 2006;176:3717-3724
Web of Science | Medline10
Bellocchio S ,Moretti S ,Perruccio K , et al. TLRs govern neutrophil activity in aspergillosis. J Immunol 2004;173:7406-7415
Web of Science | Medline11
Bochud PY ,Bochud M ,Telenti A ,Calandra T . Innate immunogenetics: a tool for exploring new frontiers of host defence. Lancet Infect Dis 2007;7:531-542
CrossRef | Web of Science | Medline12
Ascioglu S ,Rex JH ,de Pauw B , et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14
CrossRef | Web of Science | Medline13
Gauderman WJ, Morrison JM. QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies. (Available at http://hydra.usc.edu/gxe/.)
14
Przepiorka D ,Weisdorf D ,Martin P , et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-828
Web of Science | Medline15
Sullivan KM ,Agura E ,Anasetti C , et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28:250-259
Web of Science | Medline16
Ljungman P ,Griffiths P ,Paya C . Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-1097
CrossRef | Web of Science | Medline17
Marr KA ,Crippa F ,Leisenring W , et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-1533
CrossRef | Web of Science | Medline18
Bochud PY ,Hersberger M ,Taffe P , et al. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007;21:441-446
CrossRef | Web of Science | Medline19
S.A.G.E. (Statistical Analysis for Genetic Epidemiology), version 5.0. Cleveland: Case Western Reserve University, 2005.
20
Kalbfleisch JP, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
21
Kiechl S ,Lorenz E ,Reindl M , et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002;347:185-192
Full Text | Web of Science | Medline22
Lazarus R ,Klimecki WT ,Raby BA , et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. Genomics 2003;81:85-91
CrossRef | Web of Science | Medline23
Lemaitre B ,Nicolas E ,Michaut L ,Reichhart JM ,Hoffmann JA . The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-983
CrossRef | Web of Science | Medline24
Poltorak A ,He X ,Smirnova I , et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-2088
CrossRef | Web of Science | Medline25
Netea MG ,Gow NA ,Munro CA , et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J Clin Invest 2006;116:1642-1650
CrossRef | Web of Science | Medline26
Shoham S ,Huang C ,Chen JM ,Golenbock DT ,Levitz SM . Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 2001;166:4620-4626
Web of Science | Medline27
Agnese DM ,Calvano JE ,Hahm SJ , et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;186:1522-1525
CrossRef | Web of Science | Medline28
Lorenz E ,Mira JP ,Frees KL ,Schwartz DA . Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 2002;162:1028-1032
CrossRef | Web of Science | Medline29
Van der Graaf CA ,Netea MG ,Morre SA , et al. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006;17:29-34
Web of Science | Medline30
Rezazadeh M ,Hajilooi M ,Rafiei A , et al. TLR4 polymorphism in Iranian patients with brucellosis. J Infect 2006;53:206-210
CrossRef | Web of Science | Medline31
Tal G ,Mandelberg A ,Dalal I , et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 2004;189:2057-2063
CrossRef | Web of Science | Medline32
Mockenhaupt FP ,Cramer JP ,Hamann L , et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci U S A 2006;103:177-182
CrossRef | Web of Science | Medline33
Arbour NC ,Lorenz E ,Schutte BC , et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187-191
CrossRef | Web of Science | Medline34
von Aulock S ,Schroder NW ,Gueinzius K , et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysaccharide-induced cytokine release in human whole blood. J Infect Dis 2003;188:938-943
CrossRef | Web of Science | Medline35
Erridge C ,Stewart J ,Poxton IR . Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 2003;197:1787-1791
CrossRef | Web of Science | Medline36
Wacholder S ,Rothman N ,Caporaso N . Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. Cancer Epidemiol Biomarkers Prev 2002;11:513-520
Web of Science | Medline37
Lin MT ,Storer B ,Martin PJ , et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003;349:2201-2210
Full Text | Web of Science | Medline38
Lin MT ,Storer B ,Martin PJ , et al. Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. Blood 2005;106:3995-4001
CrossRef | Web of Science | Medline39
Seo KW ,Kim DH ,Sohn SK , et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 2005;36:1089-1095
CrossRef | Web of Science | Medline40
Sainz J ,Hassan L ,Perez E , et al. Interleukin-10 promoter polymorphism as risk factor to develop invasive pulmonary aspergillosis. Immunol Lett 2007;109:76-82
CrossRef | Web of Science | Medline41
Sainz J ,Perez E ,Hassan L , et al. Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007;68:41-50
CrossRef | Web of Science | Medline42
Kesh S ,Mensah NY ,Peterlongo P , et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci 2005;1062:95-103
CrossRef | Web of Science | Medline43
Vaid M ,Kaur S ,Sambatakou H ,Madan T ,Denning DW ,Sarma PU . Distinct alleles of mannose-binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitary pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clin Chem Lab Med 2007;45:183-186
CrossRef | Web of Science | Medline44
Wang R ,Lagakos SW ,Ware JH ,Hunter DJ ,Drazen JM . Statistics in medicine -- reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-2194
Full Text | Web of Science | Medline
- Citing Articles (99)
Citing Articles
1
I. Rubino, A. Coste, D. Le Roy, T. Roger, K. Jaton, M. Boeckh, M. Monod, J. P. Latge, T. Calandra, P. - Y. Bochud. (2012) Species-Specific Recognition of Aspergillus fumigatus by Toll-like Receptor 1 and Toll-like Receptor 6. Journal of Infectious Diseases
CrossRef2
A. Carvalho, C. Cunha, F. Bistoni, L. Romani. (2012) Immunotherapy of aspergillosis. Clinical Microbiology and Infection 18:2, 120-125
CrossRef3
Lili Li, Jianmin Wang, Weiping Zhang, Jianmin Yang, Li Chen, Shuqing Lv. (2012) Risk factors for invasive mold infections following allogeneic hematopoietic stem cell transplantation: A single center study of 190 recipients. Scandinavian Journal of Infectious Diseases 44:2, 100-107
CrossRef4
T. S. Plantinga, M. D. Johnson, W. K. Scott, E. van de Vosse, D. R. Velez Edwards, P. B. Smith, B. D. Alexander, J. C. Yang, D. Kremer, G. M. Laird, M. Oosting, L. A. B. Joosten, J. W. M. van der Meer, J. T. van Dissel, T. J. Walsh, J. R. Perfect, B. J. Kullberg, M. G. Netea. (2012) Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia. Journal of Infectious Diseases
CrossRef5
Vivek A Bhadri, Sara M Beckett, Catriona Duncan, Glenn M Marshall, Lesley J Ashton. (2012) Variation in Toll-like receptor 9 gene modifies the risk of infection in children treated for acute lymphoblastic leukaemia. Leukemia & Lymphoma1-9
CrossRef6
B Martín-Antonio, I Álvarez-Laderas, R Cardesa, F Márquez-Malaver, A Baez, M Carmona, J Falantes, M Suarez-Lledo, F Fernández-Avilés, C Martínez, M Rovira, I Espigado, Á Urbano-Ispizua. (2012) A constitutional variant in the transcription factor EP300 strongly influences the clinical outcome of patients submitted to allo-SCT. Bone Marrow Transplantation
CrossRef7
Nancy Bunin, Trudy Small, Paul Szabolcs, K. Scott Baker, Michael A. Pulsipher, Troy Torgerson. (2012) NCI, NHLBI/PBMTC First International Conference on Late Effects After Pediatric Hematopoietic Cell Transplantation: Persistent Immune Deficiency in Pediatric Transplant Survivors. Biology of Blood and Marrow Transplantation 18:1, 6-15
CrossRef8
Christopher C. Dvorak, Catherine M. Bollard, Javier El-Bietar, Alexandra Filipovich. (2012) Complications of Transplant for Nonmalignant Disorders: Autoimmune Cytopenias, Opportunistic Infections, and PTLD. Biology of Blood and Marrow Transplantation 18:1, S101-S110
CrossRef9
Sixto M. Leal, Eric Pearlman. (2012) The role of cytokines and pathogen recognition molecules in fungal keratitis – Insights from human disease and animal models. Cytokine
CrossRef10
Carolina Garcia-Vidal, Jordi Carratalà. (2012) Patogenia de la infección fúngica invasora. Enfermedades Infecciosas y Microbiología Clínica
CrossRef11
Michail S. Lionakis. (2011) Genetic Susceptibility to Fungal Infections in Humans. Current Fungal Infection Reports
CrossRef12
M. D. Johnson, T. S. Plantinga, E. van de Vosse, D. R. Velez Edwards, P. B. Smith, B. D. Alexander, J. C. Yang, D. Kremer, G. M. Laird, M. Oosting, L. A. B. Joosten, J. W. M. van der Meer, J. T. van Dissel, T. J. Walsh, J. R. Perfect, B.-J. Kullberg, W. K. Scott, M. G. Netea. (2011) Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study. Clinical Infectious Diseases
CrossRef13
Shmuel Shoham, Darin B. Ostrander. (2011) The Growing Role of Clinical and Genomic Databases in the Development of Antifungal Strategies. Current Fungal Infection Reports 5:4, 190-192
CrossRef14
Walter J.F.M. van der Velden, Nicole M.A. Blijlevens, J. Peter Donnelly. (2011) Genetic variants and the risk for invasive mould disease in immunocompromised hematology patients. Current Opinion in Infectious Diseases 24:6, 554-563
CrossRef15
Vanessa Espinosa, Amariliz Rivera. (2011) Cytokines and the regulation of fungus-specific CD4 T cell differentiation. Cytokine
CrossRef16
2011. Aspergillosis. , 357-396.
CrossRef17
Smita Bhatia, Stella M. Davies, K. Scott Baker, Michael A. Pulsipher, John A. Hansen. (2011) NCI, NHLBI First International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Etiology and Pathogenesis of Late Effects after HCT Performed in Childhood—Methodologic Challenges. Biology of Blood and Marrow Transplantation 17:10, 1428-1435
CrossRef18
D. C. Rosentul, T. S. Plantinga, M. Oosting, W. K. Scott, D. R. Velez Edwards, P. B. Smith, B. D. Alexander, J. C. Yang, G. M. Laird, L. A. B. Joosten, J. W. M. van der Meer, J. R. Perfect, B.-J. Kullberg, M. G. Netea, M. D. Johnson. (2011) Genetic Variation in the Dectin-1/CARD9 Recognition Pathway and Susceptibility to Candidemia. Journal of Infectious Diseases 204:7, 1138-1145
CrossRef19
Oliver A. Cornely, Franco Aversa, Perry Cook, Brian Jones, Mauricette Michallet, Thomas Shea, Carlos Vallejo. (2011) Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. European Journal of Haematology 87:4, 289-301
CrossRef20
R. S. Karthikeyan, S. M. Leal, N. V. Prajna, K. Dharmalingam, D. M. Geiser, E. Pearlman, P. Lalitha. (2011) Expression of Innate and Adaptive Immune Mediators in Human Corneal Tissue Infected With Aspergillus or Fusarium. Journal of Infectious Diseases 204:6, 942-950
CrossRef21
Zoe-Dorothea Pana, Aspasia Katragkou, Emmanuel Roilides. (2011) Immunogenetic Variability Associated with Different Susceptibility Patterns to Candida and Aspergillus Infections. Current Fungal Infection Reports 5:3, 141-150
CrossRef22
Agostinho Carvalho, Cristina Cunha, Luigina Romani. (2011) Immunity and tolerance to infections in experimental hematopoietic transplantation. Best Practice & Research Clinical Haematology 24:3, 435-442
CrossRef23
Victor E. Mulanovich, Dimitrios P. Kontoyiannis. (2011) Fungal pneumonia in patients with hematologic malignancies. Current Opinion in Infectious Diseases 24:4, 323-332
CrossRef24
Robert A. Cramer, Amariliz Rivera, Tobias M. Hohl. (2011) Immune responses against Aspergillus fumigatus. Current Opinion in Infectious Diseases 24:4, 315-322
CrossRef25
H R Ashbee, M H Gilleece. (2011) Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. Bone Marrow Transplantation
CrossRef26
Mike Hasenberg, Judith Behnsen, Sven Krappmann, Axel Brakhage, Matthias Gunzer. (2011) Phagocyte responses towards Aspergillus fumigatus. International Journal of Medical Microbiology 301:5, 436-444
CrossRef27
Michael Ok, Hermann Einsele, Juergen Loeffler. (2011) Genetic susceptibility to Aspergillus fumigatus infections. International Journal of Medical Microbiology 301:5, 445-452
CrossRef28
L. Zhou, B. Wei, C. Xing, H. Xie, X. Yu, L. Wu, S. Zheng. (2011) Polymorphism in 3′-untranslated region of toll-like receptor 4 gene is associated with protection from hepatitis B virus recurrence after liver transplantation. Transplant Infectious Disease 13:3, 250-258
CrossRef29
W J F M Van der Velden, T Feuth, W B C Stevens, J P Donnelly, N M A Blijlevens. (2011) Issues in genetic association studies: limitations of statistical analysis and biological plausibility. Bone Marrow Transplantation 46:6, 906-907
CrossRef30
Louis Yi-Ann Chai, Li-Yang Hsu. (2011) Recent advances in invasive pulmonary aspergillosis. Current Opinion in Pulmonary Medicine 17:3, 160-166
CrossRef31
Jean-Laurent Casanova, Laurent Abel, Lluis Quintana-Murci. (2011) Human TLRs and IL-1Rs in Host Defense: Natural Insights from Evolutionary, Epidemiological, and Clinical Genetics. Annual Review of Immunology 29:1, 447-491
CrossRef32
Giada Rossini, Marta Stanzani, Michele Baccarani, Giulia Tolomelli, Maria P. Landini, Vittorio Sambri, Stefania Varani. (2011) Systemic Infections Caused by Escherichia Coli in a Neutropenic Patient With Multiple TLR Gene Polymorphisms Abolished by Stem-Cell Transplantation. Transplantation 91:7, e49-e51
CrossRef33
Cristina Cunha, Fernando Rodrigues, Teresa Zelante, Franco Aversa, Luigina Romani, Agostinho Carvalho. (2011) Genetic susceptibility to aspergillosis in allogeneic stem-cell transplantation. Medical Mycology 49:S1, S137-S143
CrossRef34
Frédéric Lamoth, Ivana Rubino, Pierre-Yves Bochud. (2011) Immunogenetics of invasive aspergillosis. Medical Mycology 49:S1, S125-S136
CrossRef35
Luigina Romani. (2011) Immunity to fungal infections. Nature Reviews Immunology 11:4, 275-288
CrossRef36
Morena Caira, Mario Mancinelli, Giuseppe Leone, Livio Pagano. (2011) Invasive aspergillosis in acute leukemias: old and new risk factors and epidemiological trends. Medical Mycology 49:S1, S13-S16
CrossRef37
Marie-Christine Nicolle, Thomas Benet, Philippe Vanhems. (2011) Aspergillosis: nosocomial or community-acquired?. Medical Mycology 49:S1, S24-S29
CrossRef38
Nuran Salman, Selda H Törün, Bahar Budan, Ayper Somer. (2011) Invasive aspergillosis in hematopoietic stem cell and solid organ transplantation. Expert Review of Anti-infective Therapy 9:3, 307-315
CrossRef39
Elio Castagnola, Maura Faraci, Francesca Fioredda, Loredana Amoroso, Francesco Risso, Alessia Franceschi, Roberto Bandettini, Gian Michele Magnano, Alessio Pini Prato, Chiara Gardella, Serena Arrigo, Marco Gattorno, Giorgio Piaggio, Antonella Ciucci, Ines Lorenzi, Anna Loy, Riccardo Haupt. (2011) Invasive mould infections in newborns and children. Early Human Development 87, S67-S69
CrossRef40
A. Katragkou, A. Chatzimoschou, M. Simitsopoulou, E. Georgiadou, E. Roilides. (2011) Additive antifungal activity of anidulafungin and human neutrophils against Candida parapsilosis biofilms. Journal of Antimicrobial Chemotherapy 66:3, 588-591
CrossRef41
L. Y. A. Chai, M. G. J. de Boer, W. J. F. M. van der Velden, T. S. Plantinga, A. B. van Spriel, C. Jacobs, C. J. M. Halkes, A. G. Vonk, N. M. Blijlevens, J. T. van Dissel, P. J. Donnelly, B.-J. Kullberg, J. Maertens, M. G. Netea. (2011) The Y238X Stop Codon Polymorphism in the Human -Glucan Receptor Dectin-1 and Susceptibility to Invasive Aspergillosis. Journal of Infectious Diseases 203:5, 736-743
CrossRef42
D P Kontoyiannis. (2011) Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success. Bone Marrow Transplantation 46:2, 165-173
CrossRef43
Anna K. Person, Dimitrios P. Kontoyiannis, Barbara D. Alexander. (2011) Fungal Infections in Transplant and Oncology Patients. Hematology/Oncology Clinics of North America 25:1, 193-213
CrossRef44
L. Pagano, M. Akova, G. Dimopoulos, R. Herbrecht, L. Drgona, N. Blijlevens. (2011) Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. Journal of Antimicrobial Chemotherapy 66:Supplement 1, i5-i14
CrossRef45
Cristina Cunha, Franco Aversa, Giovanni Bistoni, Andrea Casagrande, Fernando Rodrigues, Luigina Romani, Agostinho Carvalho. (2011) Immunogenetic Profiling to Predict Risk of Invasive Fungal Diseases: Where Are We Now?. Immunological Investigations 40:7-8, 723-734
CrossRef46
Delphine Aldebert, Magali Hypolite, Gaelle Bal, Chantal Dumestre-Pérard, Rose-Laurence Bertini, Carole Rolland, Jean Boutonnat, Renée Grillot, Hervé Pelloux, Jean Paul Brion. (2011) Effects of age, gender and time on receptor expression and anti-Aspergillus functions of human phagocytes. Cellular Immunology 270:2, 230-236
CrossRef47
Louis YA Chai, Alieke G Vonk, Bart-Jan Kullberg, Mihai G Netea. (2011) Immune response to Aspergillus fumigatus in compromised hosts: from bedside to bench. Future Microbiology 6:1, 73-83
CrossRef48
Christopher C. Dvorak, Brian T. Fisher, Lillian Sung, William J. Steinbach, Michael Nieder, Sarah Alexander, Theoklis E. Zaoutis. (2011) Antifungal prophylaxis in pediatric hematology/oncology: New choices & new data. Pediatric Blood & Cancern/a-n/a
CrossRef49
Lee J. Quinton, Joseph P. Mizgerd. (2011) NF-κB and STAT3 signaling hubs for lung innate immunity. Cell and Tissue Research 343:1, 153-165
CrossRef50
C. Cunha, M. Di Ianni, S. Bozza, G. Giovannini, S. Zagarella, T. Zelante, C. D'Angelo, A. Pierini, L. Pitzurra, F. Falzetti, A. Carotti, K. Perruccio, J.-P. Latge, F. Rodrigues, A. Velardi, F. Aversa, L. Romani, A. Carvalho. (2010) Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 116:24, 5394-5402
CrossRef51
H. J. Deeg, B. M. Sandmaier. (2010) Who is fit for allogeneic transplantation?. Blood 116:23, 4762-4770
CrossRef52
Bernd Krüger, Miriam C. Banas, Andreas Walberer, Carsten A. Böger, Stefan Farkas, Ute Hoffmann, Michael Fischereder, Bernhard Banas, Bernhard K. Krämer. (2010) A comprehensive genotype–phenotype interaction of different Toll-like receptor variations in a renal transplant cohort. Clinical Science 119:12, 535-544
CrossRef53
Antonella de Luca, Silvia Bozza, Teresa Zelante, Silvia Zagarella, Carmen D'Angelo, Katia Perruccio, Carmine Vacca, Agostinho Carvalho, Cristina Cunha, Franco Aversa, Luigina Romani. (2010) Non-hematopoietic cells contribute to protective tolerance to Aspergillus fumigatus via a TRIF pathway converging on IDO. Cellular and Molecular Immunology 7:6, 459-470
CrossRef54
A Carvalho, C Cunha, M Di Ianni, L Pitzurra, T Aloisi, F Falzetti, A Carotti, F Bistoni, F Aversa, L Romani. (2010) Prognostic significance of genetic variants in the IL-23/Th17 pathway for the outcome of T cell-depleted allogeneic stem cell transplantation. Bone Marrow Transplantation 45:11, 1645-1652
CrossRef55
Cristina Cunha, Luigina Romani, Agostinho Carvalho. (2010) Cracking the Toll-like receptor code in fungal infections. Expert Review of Anti-infective Therapy 8:10, 1121-1137
CrossRef56
Anthony J. Ricketti, Dennis J. Cleri, Mehul Desai, John R. Vernaleo, David W. Unkle, Peter A. Ricketti. (2010) Right Upper Lobe Nodules in a Patient With Emphysema. Infectious Diseases in Clinical Practice 18:5, 325-328
CrossRef57
Beatriz Martín-Antonio, Miquel Granell, Álvaro Urbano-Ispizua. (2010) Genomic polymorphisms of the innate immune system and allogeneic stem cell transplantation. Expert Review of Hematology 3:4, 411-427
CrossRef58
Ronen Ben-Ami, Russell E. Lewis, Dimitrios P. Kontoyiannis. (2010) Enemy of the (immunosuppressed) state: an update on the pathogenesis of Aspergillus fumigatus infection. British Journal of Haematologyno-no
CrossRef59
A. K. Person, S. M. Chudgar, B. L. Norton, B. C. Tong, J. E. Stout. (2010) Aspergillus niger: an unusual cause of invasive pulmonary aspergillosis. Journal of Medical Microbiology 59:7, 834-838
CrossRef60
Navdeep Dhillon, Liron Walsh, Bernd Krüger, Stephen C. Ward, James H. Godbold, Mohamed Radwan, Thomas Schiano, Barbara T. Murphy, Bernd Schröppel. (2010) A single nucleotide polymorphism of Toll-like receptor 4 identifies the risk of developing graft failure after liver transplantation. Journal of Hepatology 53:1, 67-72
CrossRef61
James L. Wynn, Ofer Levy. (2010) Role of Innate Host Defenses in Susceptibility to Early-Onset Neonatal Sepsis. Clinics in Perinatology 37:2, 307-337
CrossRef62
James L. Wynn, Hector R. Wong. (2010) Pathophysiology and Treatment of Septic Shock in Neonates. Clinics in Perinatology 37:2, 439-479
CrossRef63
Rachel S. Agbeko, John W. Holloway, Meredith L. Allen, Shu Ye, Katy J. Fidler, John Pappachan, Allan Goldman, David Pontefract, John Deanfield, Nigel J. Klein, Mark J. Peters. (2010) Genetic polymorphisms in the endotoxin receptor may influence platelet count as part of the acute phase response in critically ill children. Intensive Care Medicine 36:6, 1023-1032
CrossRef64
C. GUARNER-ARGENTE, E. SÁNCHEZ, S. VIDAL, E. ROMÁN, M. CONCEPCIÓN, M. POCA, D. SÁNCHEZ, C. JUÁREZ, G. SORIANO, C. GUARNER. (2010) Toll-like receptor 4 D299G polymorphism and the incidence of infections in cirrhotic patients. Alimentary Pharmacology & Therapeutics 31:11, 1192-1199
CrossRef65
Anna K. Person, Dimitrios P. Kontoyiannis, Barbara D. Alexander. (2010) Fungal Infections in Transplant and Oncology Patients. Infectious Disease Clinics of North America 24:2, 439-459
CrossRef66
Agostinho Carvalho, Cristina Cunha, Alessandro C. Pasqualotto, Lucia Pitzurra, David W. Denning, Luigina Romani. (2010) Genetic variability of innate immunity impacts human susceptibility to fungal diseases. International Journal of Infectious Diseases 14:6, e460-e468
CrossRef67
Charulata Ramaprasad, Stephanie Pouch, David L. Pitrak. (2010) Neutrophil function after bone marrow and hematopoietic stem cell transplant. Leukemia & Lymphoma 51:5, 756-767
CrossRef68
Markus Mezger, Hermann Einsele, Juergen Loeffler. (2010) Genetic susceptibility to infections with Aspergillus fumigatus. Critical Reviews in Microbiology 36:2, 168-177
CrossRef69
Robert R. Jenq, Marcel R. M. van den Brink. (2010) Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nature Reviews Cancer 10:3, 213-221
CrossRef70
Kieren A Marr. (2010) Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Current Opinion in Oncology 22:2, 138-142
CrossRef71
Hanna Suhir, Amos Etzioni. (2010) The Role of Toll-Like Receptor Signaling in Human Immunodeficiencies. Clinical Reviews in Allergy & Immunology 38:1, 11-19
CrossRef72
Aniket Vadnerkar, Cornelius J. Clancy, Umit Celik, Samuel A. Yousem, Dimitra Mitsani, Yoshiya Toyoda, Minh-Ly Nguyen, Eun J. Kwak, Joseph Pilewski, Fernanda P. Silveira, Maria Crespo, M Hong Nguyen. (2010) Impact of Mold Infections in Explanted Lungs on Outcomes of Lung Transplantation. Transplantation 89:2, 253-260
CrossRef73
R Martino, J L Piñana, R Parody, D Valcarcel, A Sureda, S Brunet, J Briones, J Delgado, F Sánchez, N Rabella, J Sierra. (2009) Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplantation 44:11, 749-756
CrossRef74
Nikolaos G. Almyroudis, Brahm H. Segal. (2009) Editorial: Special Issue, “Invasive Fungal Diseases in Allogeneic Hematopoietic Stem Cell Transplant Recipients”. Mycopathologia 168:6, 269-270
CrossRef75
Nikolaos G. Almyroudis, Brahm H. Segal. (2009) The 2008 EORTC/MSG consensus definitions: What’s new? What’s next?. Current Fungal Infection Reports 3:4, 195-200
CrossRef76
Joshua Wolf, Monica A. Slavin. (2009) Risk-based antifungal prophylaxis in hematologic malignancy and stem cell transplantation. Current Infectious Disease Reports 11:6, 420-426
CrossRef77
Dorothy McCoy, Daryl D DePestel, Peggy L Carver. (2009) Primary Antifungal Prophylaxis in Adult Hematopoietic Stem Cell Transplant Recipients: Current Therapeutic Concepts. Pharmacotherapy 29:11, 1306-1325
CrossRef78
Andri Rauch, Silvana Gaudieri, Chloe Thio, Pierre-Yves Bochud. (2009) Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 10:11, 1819-1837
CrossRef79
Samuel O Pine, M Juliana McElrath, Pierre-Yves Bochud. (2009) Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals. AIDS 23:18, 2387-2395
CrossRef80
(2009) References. Bone Marrow Transplantation 44:8, 537-557
CrossRef81
Yonghong Li, Monica Chang, Olivia Abar, Veronica Garcia, Charles Rowland, Joseph Catanese, David Ross, Samuel Broder, Mitchell Shiffman, Ramsey Cheung, Teresa Wright, Scott L. Friedman, John Sninsky. (2009) Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. Journal of Hepatology 51:4, 750-757
CrossRef82
Marcie Tomblyn, Tom Chiller, Hermann Einsele, Ronald Gress, Kent Sepkowitz, Jan Storek, John R. Wingard, Jo-Anne H. Young, Michael A. Boeckh. (2009) Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. Biology of Blood and Marrow Transplantation 15:10, 1143-1238
CrossRef83
Viviane Balloy, Michel Chignard. (2009) The innate immune response to Aspergillus fumigatus. Microbes and Infection 11:12, 919-927
CrossRef84
Stuart M. Levitz, Charles A. Specht. (2009) Recognition of the fungal cell wall by innate immune receptors. Current Fungal Infection Reports 3:3, 179-185
CrossRef85
Agostinho Carvalho, Cristina Cunha, Alessandra Carotti, Teresa Aloisi, Ornella Guarrera, Mauro Di Ianni, Franca Falzetti, Francesco Bistoni, Franco Aversa, Lucia Pitzurra, Fernando Rodrigues, Luigina Romani. (2009) Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation. Experimental Hematology 37:9, 1022-1029
CrossRef86
P.-Y. Bochud, D. Sinsimer, A. Aderem, M. R. Siddiqui, P. Saunderson, S. Britton, I. Abraham, A. Tadesse Argaw, M. Janer, T. R. Hawn, G. Kaplan. (2009) Polymorphisms in Toll-like receptor 4 (TLR4) are associated with protection against leprosy. European Journal of Clinical Microbiology & Infectious Diseases 28:9, 1055-1065
CrossRef87
Nikolaos G Almyroudis, Brahm H Segal. (2009) Prevention and treatment of invasive fungal diseases in neutropenic patients. Current Opinion in Infectious Diseases 22:4, 385-393
CrossRef88
Ronen Ben-Ami, Russell E Lewis, Dimitrios P Kontoyiannis. (2009) Invasive mould infections in the setting of hematopoietic cell transplantation: current trends and new challenges. Current Opinion in Infectious Diseases 22:4, 376-384
CrossRef89
Richard I. Tapping. (2009) Innate immune sensing and activation of cell surface Toll-like receptors. Seminars in Immunology 21:4, 175-184
CrossRef90
Z. Erjavec, H. Kluin-Nelemans, P. E. Verweij. (2009) Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clinical Microbiology and Infection 15:7, 625-633
CrossRef91
M. C. Arendrup. (2009) Invasive fungal infections: past achievements and challenges ahead. Clinical Microbiology and Infection 15:7, 599-601
CrossRef92
Marcio Nucci, Elias Anaissie. (2009) Fungal Infections in Hematopoietic Stem Cell Transplantation and Solid-Organ Transplantation—Focus on Aspergillosis. Clinics in Chest Medicine 30:2, 295-306
CrossRef93
Robin K. Avery. (2009) Aspergillosis in hematopoietic stem cell transplant recipients: Risk factors, prophylaxis, and treatment. Current Infectious Disease Reports 11:3, 223-228
CrossRef94
Segal, Brahm H., . (2009) Aspergillosis. New England Journal of Medicine 360:18, 1870-1884
Full Text95
Johan Maertens, Wouter Meersseman, Pascal Van Bleyenbergh. (2009) New therapies for fungal pneumonia. Current Opinion in Infectious Diseases 22:2, 183-190
CrossRef96
Daniel R. Kaul, James Riddell. (2009) Approach to the immunocompromised patient with pulmonary nodules. Current Fungal Infection Reports 3:1, 45-54
CrossRef97
(2009) Toll-like Receptor 4 Polymorphisms and Aspergillosis. New England Journal of Medicine 360:6, 634-636
Full Text98
Jason W. Chien, Lue Ping Zhao, Barry Storer, Paul J. Martin, Michael Boeckh, Edus H. Warren, John A. Hansen. (2009) Improving Hematopoietic Cell Transplant Outcomes in a New Era of Genomic Research. Biology of Blood and Marrow Transplantation 15:1, 42-45
CrossRef99
Pamer, Eric G., . (2008) TLR Polymorphisms and the Risk of Invasive Fungal Infections. New England Journal of Medicine 359:17, 1836-1838
Full Text
- Letters
